Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease and psoriatic arthritis.

Type of Molecule

Biologic

Target

IL-23

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Psoriasis New Indication Phase 3
Psoriatic Arthritis New Indication Phase 2
Crohn's disease New Indication Phase 2